SOPHiA GENETICS Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 22% revenue growth, record platform usage, and strong global expansion, with adjusted gross margin at 75.4% and net dollar retention up to 117%. Guidance for 2026 is reaffirmed, with growth expected to accelerate in the second half as new customers come online.
-
Leadership transition will bring a new CEO focused on commercial growth, with the founder moving to executive chairman. The company targets accelerated revenue growth through 2026, driven by U.S. market momentum, AI-powered platform differentiation, and expanding partnerships with leading academic centers.
Fiscal Year 2025
-
Revenue grew 19% in 2025 to $77.3M, with strong Q4 and record customer signings. 2026 guidance targets 20–22% growth, improved margins, and adjusted EBITDA breakeven by year-end. Major U.S. health system wins and pharma partnerships drive future expansion.
-
Q3 2025 saw 23% revenue growth, strong new customer signings, and robust expansion in liquid biopsy and biopharma partnerships. Guidance was raised, with continued operating leverage and a healthy pipeline supporting confidence in future growth.
-
Q2 2025 saw 16% revenue growth (20% excluding biopharma), record new customer signings, and a major multi-year AI partnership with AstraZeneca. Cash burn improved 35% year-over-year, and guidance for 2025 was reaffirmed, with strong momentum in clinical and rare disease segments.
-
Gross margin remains strong with ongoing expansion, and adjusted EBITDA profitability is targeted for 2027. U.S. growth is robust, driven by larger accounts and liquid biopsy adoption, while partnerships and a growing data asset support future pharma and AI opportunities.
-
Q1 2025 saw revenue up 13% year-over-year, record adjusted gross margin of 75.7%, and improved adjusted EBITDA loss. Strong new customer signings, U.S. growth, and expanded biopharma partnerships support reaffirmed 2025 guidance and a positive long-term outlook.
-
SOPHiA GENETICS presented its AI-driven, cloud-based platform's global adoption, highlighting rapid growth in the U.S. and new liquid biopsy offerings. The company targets 10%-17% revenue growth for 2025, with upside potential from biopharma and complex testing trends.
Fiscal Year 2024
-
2024 saw solid revenue growth, strong cost control, and record new customer signings, setting up for accelerated growth in 2025 as new applications and U.S. market momentum ramp. Guidance for 2025 projects 10%-17% revenue growth, with profitability targeted by 2026.
-
The platform has expanded globally, processing over 1.8 million genomic profiles and launching new high-value applications like liquid biopsy and MSK-IMPACT. Financial performance is strong, with improved margins and cash position, and the company targets profitability by 2026 while expecting accelerated adoption and revenue growth from new offerings.
-
Q3 2024 saw clinical volume reaccelerate 16% year-over-year, offset by biopharma revenue softness, while cost management drove a 39% reduction in cash burn. MSK-ACCESS and MSK-IMPACT launches are fueling global adoption, and full-year guidance is reaffirmed.
-
U.S. bookings surged 40% in Q1, while biopharma faced 2024 challenges, prompting a shift to diversified, smaller deals and leadership changes. The cloud-based platform’s compatibility, data security, and multimodal capabilities drive adoption, with growth expected to normalize as bookings accelerate.
-
Q2 2024 saw modest revenue growth and strong margin expansion, but biopharma and EMEA headwinds led to a reduced full-year outlook. Strategic actions, new product launches, and robust pipelines position the business for reacceleration in 2025.